SAN CLEMENTE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum at 7:30 a.m. PT (10:30 a.m. ET) on Wednesday, March 22, 2023. Company management will also be participating in one-on-one meetings on Wednesday, March 22, 2023.
The fireside chat will be webcast live and can be accessed by going to the Company’s website at http://www.icumed.com, clicking on the Investors tab and clicking on the Event Calendar tab. The webcast will also be available by replay.
About ICU Medical
ICU Medical (Nasdaq:ICUI) is a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings. Our team is focused on providing quality, innovation and value to our clinical customers worldwide. ICU Medical is headquartered in San Clemente, California. More information about ICU Medical can be found at www.icumed.com
CONTACT:
ICU Medical, Inc.
Brian Bonnell, Chief Financial Officer
(949) 366-2183
ICR, Inc.
John Mills, Managing Partner
(646) 277-1254

| Last Trade: | US$146.22 |
| Daily Change: | -2.22 -1.50 |
| Daily Volume: | 104,366 |
| Market Cap: | US$3.610B |
November 06, 2025 August 07, 2025 April 07, 2025 February 27, 2025 | |

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load